177 related articles for article (PubMed ID: 33796953)
21. Targeting very early systemic sclerosis: a case-based review.
Melissaropoulos K; Kraniotis P; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
Rheumatol Int; 2019 Nov; 39(11):1961-1970. PubMed ID: 31254002
[TBL] [Abstract][Full Text] [Related]
22. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.
Agostini E; De Luca G; Bruni C; Bartoli F; Tofani L; Campochiaro C; Pacini G; Moggi-Pignone A; Guiducci S; Bellando-Randone S; Shoenfeld Y; Dagna L; Matucci-Cerinic M
Autoimmun Rev; 2021 Dec; 20(12):102981. PubMed ID: 34718166
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis.
Liakouli V; Ciaffi J; Ursini F; Ruscitti P; Meliconi R; Ciccia F; Cipriani P; Giacomelli R
Expert Rev Clin Immunol; 2020 Sep; 16(9):931-942. PubMed ID: 32893688
[TBL] [Abstract][Full Text] [Related]
24. Rituximab for rapidly progressive juvenile systemic sclerosis.
Zulian F; Dal Pozzolo R; Meneghel A; Castaldi B; Marcolongo R; Caforio ALP; Martini G
Rheumatology (Oxford); 2020 Dec; 59(12):3793-3797. PubMed ID: 32442284
[TBL] [Abstract][Full Text] [Related]
25. Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial.
Ebata S; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Yoshihide A; Yoshizaki A; Sato S
Rheumatology (Oxford); 2022 Nov; 61(11):4364-4373. PubMed ID: 35136981
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis.
Yalçinkaya Y; Artim Esen B; Amikishiyev S; Aliyeva N; Gül A; Öcal L; Inanç M
Turk J Med Sci; 2023; 53(6):1704-1712. PubMed ID: 38813512
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of mesenchymal stem cells in the treatment of systemic sclerosis: a systematic review and meta-analysis.
Cui J; Jin L; Ding M; He J; Yang L; Cui S; Wang X; Ma J; Liu A
Stem Cell Res Ther; 2022 Mar; 13(1):118. PubMed ID: 35313985
[TBL] [Abstract][Full Text] [Related]
28. Functioning and health-related quality of life in Chinese patients with systemic sclerosis: a case-control study.
Chan PT; Mok CC; Chan KL; Ho LY
Clin Rheumatol; 2014 May; 33(5):659-66. PubMed ID: 24531870
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature.
Narváez J; Pirola JP; LLuch J; Juarez P; Nolla JM; Valenzuela A
Autoimmun Rev; 2019 Mar; 18(3):262-269. PubMed ID: 30639647
[TBL] [Abstract][Full Text] [Related]
31. Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Asano Y; Oba K; Sato S
J Dermatol; 2020 Jul; 47(7):796-800. PubMed ID: 32383266
[TBL] [Abstract][Full Text] [Related]
32. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Sirinian C; Karampetsou M; Yiannopoulos G; Andonopoulos AP
Rheumatology (Oxford); 2010 Feb; 49(2):271-80. PubMed ID: 19447770
[TBL] [Abstract][Full Text] [Related]
33. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.
Daoussis D; Tsamandas A; Antonopoulos I; Filippopoulou A; Papachristou DJ; Papachristou NI; Andonopoulos AP; Liossis SN
Arthritis Res Ther; 2016 May; 18(1):118. PubMed ID: 27208972
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study.
Yılmaz DD; Borekci S; Musellim B
Clin Rheumatol; 2021 Oct; 40(10):4071-4079. PubMed ID: 34056665
[TBL] [Abstract][Full Text] [Related]
35. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
36. Effects of treatment with rituximab on microcirculation in patients with long-term systemic sclerosis.
Vilela VS; da Silva BRA; da Costa CH; Lopes AJ; Levy RA; Rufino R
BMC Res Notes; 2018 Dec; 11(1):874. PubMed ID: 30526656
[TBL] [Abstract][Full Text] [Related]
37. Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience.
Castellví I; Elhai M; Bruni C; Airò P; Jordan S; Beretta L; Codullo V; Montecucco CM; Bokarewa M; Iannonne F; Balbir A; Hsu VM; Distler O; Matucci-Cerinic M; Allanore Y;
Semin Arthritis Rheum; 2020 Dec; 50(6):1489-1493. PubMed ID: 32165035
[TBL] [Abstract][Full Text] [Related]
38. Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience.
Panopoulos ST; Tektonidou MG; Bournia VK; Arida A; Sfikakis PP
J Rheumatol; 2022 Jan; 49(1):68-73. PubMed ID: 34393104
[TBL] [Abstract][Full Text] [Related]
39. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
[TBL] [Abstract][Full Text] [Related]
40. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.
Melsens K; Vandecasteele E; Deschepper E; Badot V; Blockmans D; Brusselle G; De Langhe E; De Pauw M; Debusschere C; Decuman S; Deroo L; Houssiau F; Lenaerts J; Piette Y; Thevissen K; Vanthuyne M; Westhovens R; Wijnant S; De Keyser F; Smith V
Acta Clin Belg; 2018 Apr; 73(2):119-125. PubMed ID: 28891418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
